RESUMEN
Estrogens have been shown to regulate the immune system and modulate multiple autoimmune diseases. 17α-ethinyl estradiol (EE), a synthetic analog of 17ß-estradiol, is prescribed commonly and found in oral contraceptives and hormone replacement therapies. Surprisingly, few studies have investigated the immunoregulatory effects of exposure to EE, especially in autoimmunity. In this study, we exposed autoimmune-prone female MRL/lpr mice to a human-relevant dose of EE through the oral route of exposure. Since lupus patients are prone to infections, groups of mice were injected with viral (Imiquimod, a TLR7 agonist) or bacterial (ODN 2395, a TLR9 agonist) surrogates. We then evaluated autoimmune disease parameters, kidney disease, and response to in vivo TLR7/9 pathogenic signals. EE-exposed mice had increased proteinuria as early as 7 weeks of age. Proteinuria, blood urea nitrogen, and glomerular immune complex deposition were also exacerbated when compared to controls. Production of cytokines by splenic leukocytes were altered in EE-exposed mice. Our study shows that oral exposure to EE, even at a very low dose, can exacerbate azotemia, increase clinical markers of renal disease, enhance glomerular immune complex deposition, and modulate TLR7/9 cytokine production in female MRL/lpr mice. This study may have implications for EE-exposure risk for genetically lupus-prone individuals.
Asunto(s)
Etinilestradiol/toxicidad , Enfermedades del Complejo Inmune/inmunología , Nefritis Lúpica/inmunología , Glicoproteínas de Membrana/agonistas , Receptor Toll-Like 7/agonistas , Receptor Toll-Like 9/agonistas , Animales , Autoanticuerpos/análisis , Nitrógeno de la Urea Sanguínea , Creatinina/sangre , Citocinas/biosíntesis , Etinilestradiol/administración & dosificación , Femenino , Imiquimod/farmacología , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/tratamiento farmacológico , Enfermedades del Complejo Inmune/genética , Inmunoglobulina G/análisis , Glomérulos Renales/inmunología , Glomérulos Renales/patología , Leucocitos/metabolismo , Nefritis Lúpica/inducido químicamente , Nefritis Lúpica/tratamiento farmacológico , Ratones , Ratones Endogámicos MRL lpr , Proteinuria/etiología , Bazo/patologíaRESUMEN
Prevalence of immune-mediated glomerulonephritis has increased in preclinical toxicity studies, with more frequent use of biotherapeutic agents (especially antigenic humanized molecules) and antisense oligonucleotide (ASO) therapies. Immune complex disease affects a small number of study monkeys, often correlates with antidrug antibody (ADA) titers, and occurs at a dose that favors immune complex formation or impedes clearance. While preclinical glomerulonephritis often fails to correlate with evidence of glomerular or vascular injury in human clinical trials and is not considered predictive, additional animal investigative immunohistochemical work may be performed to substantiate evidence for immune complex pathogenesis. While ADA is most commonly encountered as a predisposing factor with biotherapeutic agents, complement activation may occur without circulating complexes, and other mechanisms of non-ADA immune-mediated glomerulonephritis have been observed including nonendogenous immune aggregates and immunoregulatory pharmacology. Although glomerulonephritis associated with oligonucleotide therapies has been noted occasionally in preclinical studies and more rarely with human patients, pathophysiologic mechanisms involved appear to be different between species and preclinical cases are not considered predictive for humans. ADA is not involved in oligonucleotide-associated cases, and complement fixation plays a more important role in monkeys. Recent screening of ASOs for proinflammatory activity appears to have decreased glomerulonephritis incidence preclinically.
Asunto(s)
Terapia Biológica/efectos adversos , Glomerulonefritis/inducido químicamente , Oligonucleótidos Antisentido/toxicidad , Animales , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Enfermedades del Complejo Inmune/inducido químicamenteRESUMEN
This article summarizes a continuing education presentation on immunogenicity that was part of a continuing education course entitled, "Clinical Pathology of Biotherapeutics." Immunogenicity of a biotherapeutic can have diverse impacts including altered systemic exposure and pharmacologic responses and, in a fraction of the cases, safety concerns including cross-reactive neutralization of endogenous proteins or sequela related to immune complex disease (ICD). In most cases, immune complexes are readily cleared from circulation; however, based on physiochemical properties, insoluble complexes form, activate complement, and deposit in tissues. Using published information and personal experience, a set of repeat-dose monkey toxicity studies with manifestations suggestive of ICD was reviewed to summarize the spectrum of clinical and pathology findings. The most common live-phase observation linked to ICD was an acute postdosing reaction following multiple dose administrations characterized by generalized collapse and attributed to acute complement activation. Less common live-phase observations were related to syndromes such as a consumptive coagulopathy or a protein losing nephropathy. The most common histologic change attributed to ICD was multi-organ vascular/perivascular inflammation followed by glomerulonephritis. The presentation concluded with a description of the challenges in assessing the relevance of immunogenicity-related reaction in monkey to human clinical use.
Asunto(s)
Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/inmunología , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/inmunología , Animales , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos/métodos , Humanos , ToxicologíaAsunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Urticaria/tratamiento farmacológico , Adulto , Anticuerpos Monoclonales Humanizados/efectos adversos , Asma/tratamiento farmacológico , Enfermedad Crónica , Esquema de Medicación , Eosinofilia/tratamiento farmacológico , Femenino , Volumen Espiratorio Forzado/efectos de los fármacos , Humanos , Enfermedades del Complejo Inmune/inducido químicamente , Resultado del TratamientoAsunto(s)
Anticuerpos Monoclonales/efectos adversos , Complejo Antígeno-Anticuerpo/inmunología , Glomerulonefritis/inducido químicamente , Enfermedades del Complejo Inmune/inducido químicamente , Glomerulonefritis/inmunología , Humanos , Enfermedades del Complejo Inmune/inmunología , Masculino , Panitumumab , Adulto JovenAsunto(s)
Complejo Antígeno-Anticuerpo/metabolismo , Antineoplásicos Fitogénicos/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Glomerulonefritis/inducido químicamente , Enfermedades del Complejo Inmune/inducido químicamente , Paclitaxel/efectos adversos , Adulto , Femenino , Humanos , Enfermedades del Complejo Inmune/inmunologíaRESUMEN
There were performed the studies of genotoxic stress and the ways of immunocompetent cells death (apoptosis and necrosis) in the modeling of immune system damage by immunization of CBA mice with the bovine serum albumin. Immunofluorescence studies of immunized mice were established the fixation of immune complexes in liver tissue, spleen, kidney and the aorta. Histological studies of these organs showed vascular system affection and, to a lesser extent, parenchyma. It has been shown that DNA comets index increases in 1,4 time in the lymph node cells and in 1,5 time in the thymus cells in the presence of BSA immunization. We also observed an increase in the number of cells with maximum damage DNA thymus preparations (3.4 fold) and lymph nodes (3.3-fold), respectively, indicating strong genotoxic stress. There were shown the reduce of live ICC number and their death increase, including the pro-inflammatory and immunogenic necrotic way. In that way, data which were obtained on the experimental model is evidenced that generalized immunecomplex pathologic process leads to DNA damage and ICC death both central and peripheral organs of the immune system. ICC genotoxic stress and their death amplification by the necrotic way may play a significant role in the immunecomplex deseases development. These factors of peripheral blood lymphocytes can serve as a prospective test system for assessing the severity of autoimmune and immune complex diseases and their treatment effectiveness.
Asunto(s)
Complejo Antígeno-Anticuerpo/sangre , Daño del ADN/inmunología , Enfermedades del Complejo Inmune/patología , Necrosis/patología , Timo/patología , Animales , Aorta/inmunología , Aorta/metabolismo , Aorta/patología , Apoptosis/inmunología , Bovinos , Ensayo Cometa , Modelos Animales de Enfermedad , Femenino , Enfermedades del Complejo Inmune/sangre , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/inmunología , Inmunización , Riñón/inmunología , Riñón/metabolismo , Riñón/patología , Ganglios Linfáticos/inmunología , Ganglios Linfáticos/metabolismo , Ganglios Linfáticos/patología , Ratones , Ratones Endogámicos CBA , Necrosis/inducido químicamente , Necrosis/inmunología , Necrosis/metabolismo , Albúmina Sérica Bovina/administración & dosificación , Bazo/inmunología , Bazo/metabolismo , Bazo/patología , Timo/inmunología , Timo/metabolismoRESUMEN
AIM: Interactions between the co-stimulatory molecule programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, constrain T-cell responses and help maintain peripheral tolerance. Glomerulonephritis can result from a variety of antigens, both self and foreign, and from humoural and cellular effector responses. These studies aimed to define the role of PD1 and its ligands in circulating immune complex glomerulonephritis induced by immunity to a foreign antigen. METHODS: Immune complex glomerulonephritis was initiated by injecting BALB/c mice with horse spleen apoferritin intraperitoneally daily for 14 days. Inhibitory anti-mouse PD-1, anti-PD-L1 or anti-PD-L2 antibodies were administered every other day. Renal disease and immune responses were studied. RESULTS: Daily injection of horse spleen apoferritin-induced proliferative immune complex glomerulonephritis in control antibody-treated mice, but inhibiting PD-1 did not augment renal injury. Specifically, blocking PD-1 did not increase serum antigen-specific antibodies or increase glomerular immunoglobulin G deposition, the hallmark of injury in this model. Furthermore, C3 deposition was unaffected and glomerular macrophages were reduced after anti-PD-1 antibodies. However, anti-PD-1 administration did increase splenocyte proliferation and cytokine production including interferon-γ, interleukin (IL)-4, and IL-17, but not IL-10. Neutralizing either PD-L1 or PD-L2 alone did not result in major alterations in renal injury. CONCLUSION: The endogenous PD-1/PD-L pathway does not limit acute experimental foreign antigen-induced circulating immune complex glomerulonephritis.
Asunto(s)
Antígenos , Apoferritinas , Antígeno B7-H1/inmunología , Glomerulonefritis/inmunología , Enfermedades del Complejo Inmune/inmunología , Glomérulos Renales/inmunología , Proteína 2 Ligando de Muerte Celular Programada 1/inmunología , Receptor de Muerte Celular Programada 1/inmunología , Animales , Anticuerpos/administración & dosificación , Antígeno B7-H1/antagonistas & inhibidores , Antígeno B7-H1/metabolismo , Células Cultivadas , Citocinas/inmunología , Citocinas/metabolismo , Modelos Animales de Enfermedad , Glomerulonefritis/inducido químicamente , Glomerulonefritis/metabolismo , Glomerulonefritis/patología , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/metabolismo , Enfermedades del Complejo Inmune/patología , Inmunidad Humoral , Inmunoglobulina G/inmunología , Inmunoglobulina G/metabolismo , Mediadores de Inflamación/inmunología , Mediadores de Inflamación/metabolismo , Glomérulos Renales/efectos de los fármacos , Glomérulos Renales/metabolismo , Glomérulos Renales/patología , Macrófagos/inmunología , Macrófagos/metabolismo , Masculino , Ratones Endogámicos BALB C , Proteína 2 Ligando de Muerte Celular Programada 1/antagonistas & inhibidores , Proteína 2 Ligando de Muerte Celular Programada 1/metabolismo , Receptor de Muerte Celular Programada 1/antagonistas & inhibidores , Receptor de Muerte Celular Programada 1/metabolismo , Transducción de Señal , Bazo/inmunología , Bazo/metabolismo , Factores de TiempoRESUMEN
Contagious bovine pleuropneumonia (CBPP) is a serious respiratory disease of cattle caused by Mycoplasma mycoides subsp. mycoides. Current vaccines against CBPP induce short-lived immunity and can cause severe postvaccine reactions. Previous studies have identified the N terminus of the transmembrane lipoprotein Q (LppQ-N') of M. mycoides subsp. mycoides as the major antigen and a possible virulence factor. We therefore immunized cattle with purified recombinant LppQ-N' formulated in Freund's adjuvant and challenged them with M. mycoides subsp. mycoides. Vaccinated animals showed a strong seroconversion to LppQ, but they exhibited significantly enhanced postchallenge glomerulonephritis compared to the placebo group (P = 0.021). Glomerulonephritis was characterized by features that suggested the development of antigen-antibody immune complexes. Clinical signs and gross pathological scores did not significantly differ between vaccinated and placebo groups. These findings reveal for the first time the pathogenesis of enhanced disease as a result of antibodies against LppQ during challenge and also argue against inclusion of LppQ-N' in a future subunit vaccine for CBPP.
Asunto(s)
Vacunas Bacterianas/efectos adversos , Enfermedades de los Bovinos/inducido químicamente , Enfermedades del Complejo Inmune/veterinaria , Infecciones por Mycoplasma/prevención & control , Mycoplasma mycoides/inmunología , Vacunación/efectos adversos , Vacunación/métodos , Animales , Proteínas Bacterianas/administración & dosificación , Proteínas Bacterianas/inmunología , Vacunas Bacterianas/administración & dosificación , Vacunas Bacterianas/inmunología , Bovinos , Método Doble Ciego , Adyuvante de Freund/administración & dosificación , Glomerulonefritis/inducido químicamente , Glomerulonefritis/veterinaria , Enfermedades del Complejo Inmune/inducido químicamente , Vacunas de Subunidad/administración & dosificación , Vacunas de Subunidad/efectos adversos , Vacunas de Subunidad/inmunologíaRESUMEN
Henoch-Schönlein purpura (HSP) is a common systemic vasculitis in children. Animal models of HSP are needed to better understand the mechanism of HSP. Here, we investigated hematologic and immunologic profiles in HSP rat and rabbit models. Models were established with ovalbumin (OVA) based on type III hypersensitivity. During the acute phase, the models exhibited varying degrees of cutaneous purpura, joint inflammatory response, gastrointestinal bleeding, glomerular capsule protein exudation, vascular dilatation, and increased IgA expression and immune complex deposition. Twenty four hours after antigen challenge, compared with the controls, the models showed a significantly increased white blood cell count and granulocytes count and percentage, decreased number and percentage of lymphocytes, no change in platelet concentration, significantly increased serum IL-4 and TNF-α levels, and decreased CD4(+) T cell, CD4/CD8 ratio, and C3 and C4 levels. Compared with the hematologic and immunologic profiles in pediatric HSP patients, the rat and rabbit HSP models can mimic pediatric HSP characteristics. Our studies provide two useful animal models for further investigations of the pathogenesis, diagnosis, drug screening and treatment of HSP.
Asunto(s)
Citocinas/inmunología , Modelos Animales de Enfermedad , Vasculitis por IgA/inducido químicamente , Vasculitis por IgA/inmunología , Linfocitos/inmunología , Ovalbúmina , Animales , Femenino , Humanos , Vasculitis por IgA/sangre , Enfermedades del Complejo Inmune/sangre , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/inmunología , Masculino , Conejos , Ratas , Ratas Sprague-Dawley , Especificidad de la EspecieRESUMEN
Advanced glycation end products (AGEs) are thought to contribute to the abnormal lipoprotein profiles and increased risk of cardiovascular disease in patients with diabetes and renal failure. D-ribose is one of the naturally occurring pentose monosaccharide present in all living cells and is a key component of numerous biomolecules involved in many important metabolic pathways. Formation of D-ribose derived glycated low density lipoprotein (LDL) has been previously demonstrated but no studies have been performed to assess the immune complex deposition in the kidney of rabbits immunized with glycated LDL. In this study, LDL was glycated with D-ribose, and it was further used as an immunogen for immunizing NZW female rabbits. The results showed that female rabbits immunized with D-ribose modified LDL induced antibodies as detected by direct binding and competitive ELISA. The modified LDL was found to be highly immunogenic eliciting high titer immunogen-specific antibodies, while the native forms were moderately immunogenic. The induced antibodies from modified LDL exhibited wide range of heterogeneity in recognizing various proteins and amino acids conformers. Furthermore, our histopathological results illustrated the deposits of immune complex in glomerular basement membrane in rabbits immunized with D-ribose-LDL.
Asunto(s)
Complejo Antígeno-Anticuerpo/inmunología , Membrana Basal Glomerular/inmunología , Productos Finales de Glicación Avanzada/inmunología , Enfermedades del Complejo Inmune/inmunología , Lipoproteínas LDL/inmunología , Ribosa/inmunología , Animales , Femenino , Membrana Basal Glomerular/patología , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/patología , ConejosRESUMEN
Two 6-month repeat-dose toxicity studies in cynomolgus monkeys illustrated immune complex-mediated adverse findings in individual monkeys and identified parameters that potentially signal the onset of immune complex-mediated reactions following administration of RN6G, a monoclonal antibody (mAb). In the first study, 3 monkeys exhibited nondose-dependent severe clinical signs accompanied by decreased erythrocytes with increased reticulocytes, neutrophilia, monocytosis, thrombocytopenia, coagulopathy, decreased albumin, azotemia, and increased serum levels of activated complement products, prompting unscheduled euthanasia. Histologically, immunohistochemical localization of RN6G was associated with monkey immunoglobulin and complement components in glomeruli and other tissues, attributable to immune complex disease (ICD). All 3 animals also had anti-RN6G antibodies and decreased plasma levels of RN6G. Subsequently, an investigational study was designed and conducted with regulatory agency input to detect early onset of ICD and assess reversibility to support further clinical development. Dosing of individual animals ceased when biomarkers of ICD indicated adverse findings. Of the 12 monkeys, 1 developed anti-RN6G antibodies and decreased RN6G exposure that preceded elevations in complement products, interleukin-6, and coagulation parameters and decreases in albumin and fibrinogen. All findings in this monkey, except for antidrug antibody (ADA), reversed after cessation of dosing without progressing to adverse sequelae typically associated with ICD.
Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Biomarcadores/sangre , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Enfermedades del Complejo Inmune/sangre , Animales , Anticuerpos Monoclonales/sangre , Proteína C-Reactiva/metabolismo , Complejo de Ataque a Membrana del Sistema Complemento/metabolismo , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Femenino , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/patología , Inmunohistoquímica , Interferón gamma/sangre , Interleucina-1beta/sangre , Interleucina-6/sangre , Macaca fascicularis , Masculino , Microscopía Electrónica de Transmisión , Factor de Necrosis Tumoral alfa/sangre , UrinálisisRESUMEN
OBJECTIVE: To describe 2 cases of vasculitis that were attributed to a type III hypersensitivity reaction in critically ill dogs occurring 8-16 days postadministration of human serum albumin (HSA). CASE OR SERIES SUMMARY: Skin biopsies were obtained from 3 different sites in 2 critically ill dogs that developed vasculitis 8-16 days following treatment with HSA. Histopathological findings from both dogs indicated epidermal pallor, widespread edema and hemorrhage, degenerative neutrophilic perivascular infiltrates, and multifocal areas of neutrophilic or leukocytoclastic vasculitis. Immunohistochemical staining using an anti-human serum albumin rabbit antibody suggested that the antigen-antibody complexes seen in the dermis were associated with the administration of HSA. NEW OR UNIQUE INFORMATION PROVIDED: In this case series, we documented a leukocytoclastic vasculitis and probable antigen-antibody complexes to human albumin in the dermis of 2 critically ill dogs after administration of HSA. Previously, type III hypersensitivity reactions had only been reported in healthy dogs that had received HSA. This report also describes the potential use of immunohistochemical staining to detect the HSA antigen in tissue sections through the use of specifically labeled antibodies.
Asunto(s)
Enfermedad Crítica , Enfermedades de los Perros/inducido químicamente , Hipersensibilidad a las Drogas/veterinaria , Enfermedades del Complejo Inmune/veterinaria , Albúmina Sérica/efectos adversos , Vasculitis/veterinaria , Animales , Enfermedades de los Perros/patología , Perros , Femenino , Humanos , Enfermedades del Complejo Inmune/inducido químicamente , Masculino , Albúmina Sérica/inmunología , Vasculitis/inducido químicamenteRESUMEN
OBJECTIVE: To observe the histopathological and ultrastructural features of coronary artery vasculitis in rabbits caused by repeated intravenous injections of bovine serum albumin (BSA), mimicking Kawasaki disease. MATERIALS AND METHODS: Twenty weanling rabbits were randomly and equally divided into treatment groups for BSA or normal saline (NS), and administered the respective treatment by intravenous injection once every 12 days for two cycles. Six weeks after the first treatment, rabbits underwent coronary angiography and coronary arteries were removed within 1 h. Histopathological examination was performed by light, scanning electron, and transmission electron microscopy. RESULTS: Coronary arteriography revealed that 3 rabbits (3/10) in the BSA group had various levels of dilation and narrowing of the left coronary arteries, while histological examination showed that 10 rabbits (10/10) had infiltration of the coronary arteries by inflammatory cells. Incomplete endothelium, breakage of elastic fiber, and intimal thickening were also observed in 8 rabbits (8/10) from the BSA group. Ultrastructurally, in 3 rabbits (3/10) in the BSA group, leukocyte migration, shedding of endothelial microparticles from the plasma membranes, incomplete endothelium, abscission of endothelial cells, breakage of the internal elastic lamina (IEL), degeneration of smooth muscle cells in the medial membrane, and swollen mitochondria were detected. By contrast, the IEL of the NS control group was continuous and of uniform thickness. CONCLUSION: This rabbit model of coronary arteritis displayed histopathological and ultrastructural features similar to those of Kawasaki disease in humans. Breakage of the IEL, a key factor in aneurysm formation, was observed in the coronary arteries. Therefore weanling rabbits may serve as an experimental model for immune complex vasculitis involving coronary arteries that mimics Kawasaki disease.
Asunto(s)
Enfermedad de la Arteria Coronaria/patología , Vasos Coronarios/ultraestructura , Modelos Animales de Enfermedad , Enfermedades del Complejo Inmune/patología , Síndrome Mucocutáneo Linfonodular/patología , Vasculitis/patología , Animales , Bovinos , Angiografía Coronaria , Enfermedad de la Arteria Coronaria/inducido químicamente , Enfermedad de la Arteria Coronaria/inmunología , Vasos Coronarios/efectos de los fármacos , Vasos Coronarios/inmunología , Endotelio Vascular/ultraestructura , Femenino , Humanos , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/inmunología , Inyecciones Intravenosas , Masculino , Microscopía Electrónica de Rastreo , Síndrome Mucocutáneo Linfonodular/etiología , Síndrome Mucocutáneo Linfonodular/inmunología , Conejos , Albúmina Sérica Bovina/toxicidad , Vasculitis/inducido químicamente , Vasculitis/inmunología , Vasodilatación/efectos de los fármacosRESUMEN
BACKGROUND: In this study, the effect of intravitreal injection of bevacizumab on choroidal blood vessels was examined in primate eyes. METHODS: Four Cynomolgus monkeys received an intravitreal injection of 1.25 mg bevacizumab. The eyes were enucleated on days 1, 4, 7 and 14. For each animal, one eye was embedded in paraffin whereas the other eye was embedded for electron microscopy. Seven untreated or PBS (phosphate buffered saline)-injected monkeys were used as controls. RESULTS: Thrombotic microangiopathy was found in the choriocapillaris and choroidal vessels of all eight injected eyes. Acute microangiopathy was characterized ultrastructurally as swelling of the endothelium, loss of fenestrations and complete collapse of the capillaries, and was commonly observed in bevacizumab-treated eyes. Quantitative analysis showed reduction of the lumina of the choriocapillaris in the eyes of three of the monkeys. Bevacizumab was frequently localized inside the blood vessels, often filling the entire breadth of the vessels, and formed clusters with blood cells. Death of photoreceptors occurred in two monkeys. CONCLUSIONS: This study indicate that intravitreal injection of bevacizumab in monkeys induces activation of platelets, degranulation of thrombocytes and neutrophils, formation of immune complexes, thrombotic microangiopathy and alteration of the blood flow in choroidal vessels.
Asunto(s)
Inhibidores de la Angiogénesis/efectos adversos , Anticuerpos Monoclonales Humanizados/efectos adversos , Coroides/irrigación sanguínea , Enfermedades del Complejo Inmune/inducido químicamente , Microangiopatías Trombóticas/inducido químicamente , Inhibidores de la Angiogénesis/administración & dosificación , Animales , Anticuerpos Monoclonales Humanizados/administración & dosificación , Apoptosis/efectos de los fármacos , Bevacizumab , Plaquetas/fisiología , Capilares , Degranulación de la Célula , Coroides/ultraestructura , Técnica del Anticuerpo Fluorescente Indirecta , Enfermedades del Complejo Inmune/patología , Inyecciones Intravítreas , Macaca fascicularis , Microscopía Fluorescente , Células Fotorreceptoras de Vertebrados/patología , Activación Plaquetaria/efectos de los fármacos , Microangiopatías Trombóticas/patología , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidoresRESUMEN
AIM: Renal expression of matrix metalloproteinases (MMP) and tissue inhibitors of MMP (TIMP) contribute to the development of tubulointerstitial fibrosis characteristic of progressive forms of primary glomerulonephritis (GN). The aim of this study was to investigate the therapeutic effect of MMP inhibitor, doxycycline, administration in an experimental rat model of immune-complex nephritis (ICN). METHODS: The induction of immune-complex glomerulonephritis was carried out by the administration of an i.v. dose of 2 mg bovine serum albumin (BSA) daily for 28 days after 8 weeks of s.c. immunization with 1 mg of BSA in complete Freund's adjuvant. Doxycycline (30 mg/kg) was given daily (in groups 2 and 4) by gavage for 28 days. RESULTS: Animals treated with doxycycline showed significant reduction in glomerular area and cell proliferation than non-treated controls. Glomerular deposition of immunoglobulin (Ig)G and C3 was less intense in treated rats than non-treated controls. Although not statistically significant, interstitial inflammation was less intense in treated rats than non-treated controls. Glomerular expression of MMP-9 by immunoflourescence was significantly inhibited in the treated group. In addition pro-MMP-2 on gelatin zymography was importantly suppressed by doxycycline in ICN. CONCLUSION: Doxycycline, in addition to its antibiotic property, may, following further investigation, provide a possible survival benefit in proliferative glomerulonephritis.
Asunto(s)
Proliferación Celular/efectos de los fármacos , Doxiciclina/farmacología , Glomerulonefritis/prevención & control , Enfermedades del Complejo Inmune/prevención & control , Glomérulos Renales/efectos de los fármacos , Inhibidores de la Metaloproteinasa de la Matriz , Inhibidores de Proteasas/farmacología , Animales , Colágeno Tipo IV/metabolismo , Modelos Animales de Enfermedad , Ensayo de Inmunoadsorción Enzimática , Técnica del Anticuerpo Fluorescente , Adyuvante de Freund , Glomerulonefritis/inducido químicamente , Glomerulonefritis/enzimología , Glomerulonefritis/patología , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/enzimología , Enfermedades del Complejo Inmune/patología , Inmunohistoquímica , Glomérulos Renales/enzimología , Glomérulos Renales/patología , Masculino , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Ratas , Ratas Wistar , Albúmina Sérica Bovina , Factores de Tiempo , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Inhibidor Tisular de Metaloproteinasa-2/metabolismoRESUMEN
The extensive use of therapeutic monoclonal antibodies in clinic has shown that toxic effects may occur in patients. Examples such as muromonab (anti-CD3) and recently TGN1412 (anti-CD28) clearly establish that prediction of toxic effects for these targeted therapies is still complex. These undesirable effects can be classified in four categories: cytokine release syndrome, auto-immune diseases, organ toxicity and opportunistic infections. Immunogenicity, which is highly variable depending on the degree of humanization, could also potentially lead to adverse effects due to immune-complexes formation. The recent accident observed with the anti-CD28 TGN1412 has led to the conclusion that the relative confidence in the safety of monoclonal antibodies should be revised. In addition, the prediction of non-clinical models is rather limited and extrapolation of animal results to the human situation should be performed with caution. A better knowledge of the cellular target of the antibodies and of their mechanisms of action and the identification of risk factors (immune cell activation, wide expression of the target...) should improve the clinical safety of these products. .
Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Animales , Anticuerpos Antiidiotipos/biosíntesis , Anticuerpos Antiidiotipos/inmunología , Anticuerpos Monoclonales/uso terapéutico , Enfermedades Autoinmunes/inducido químicamente , Cardiomiopatías/inducido químicamente , Citocinas/metabolismo , Sistemas de Liberación de Medicamentos , Erupciones por Medicamentos/etiología , Evaluación Preclínica de Medicamentos , Enfermedades Gastrointestinales/inducido químicamente , Humanos , Enfermedades del Complejo Inmune/inducido químicamente , Terapia de Inmunosupresión/efectos adversos , Ratones , Infecciones Oportunistas/etiologíaRESUMEN
BACKGROUND: The kidney is one of the organs affected in patients with propylthiouracil (PTU)-associated antineutrophil cytoplasmic antibody (ANCA)-positive vasculitis. We present a series of Chinese patients with renal involvement in PTU-associated ANCA-positive vasculitis and describe their clinical and pathological characteristics. METHODS: Clinical and pathological data from patients with PTU-associated ANCA-positive vasculitis with renal involvement, diagnosed in Peking University First Hospital, were collected and analyzed retrospectively. RESULTS: Nineteen patients with PTU-associated ANCA-positive vasculitis were treated at Peking University First Hospital between December 1999 and December 2005, and 15 of them had renal involvement. Of the 15 patients, 13 were female and 2 were male, with an average age of 26.3 +/- 11.8 years. All 15 patients were perinuclear ANCA positive with specificities to myeloperoxidase (15 of 15), cathepsin G (9 of 15), human leukocyte elastase (8 of 15), lactoferrin (7 of 15), azurocidin (5 of 15), and proteinase 3 (4 of 15). Duration of PTU administration was 43.0 +/- 31.2 months. All 15 patients had clinical markers of renal involvement, including hematuria (100%), proteinuria (100%), and renal function abnormality (47%). All 15 patients underwent percutaneous renal biopsy. Ten patients had necrotizing crescentic glomerulonephritis, and 7 of these 10 patients had immune complex deposition. Three patients had minimal involvement, 2 patients had immunoglobulin A nephropathy, and 2 patients had membranous nephropathy. PTU treatment was discontinued in all 15 patients. All except 2 patients with minimal renal involvement received immunosuppressive treatment. Eleven of 15 patients achieved complete clinical remission. CONCLUSION: Renal involvement in our case series of patients with PTU-associated ANCA-positive vasculitis was heterogeneous, and nearly half our patients had renal immune complex deposition.
Asunto(s)
Anticuerpos Anticitoplasma de Neutrófilos/sangre , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades Renales/inducido químicamente , Propiltiouracilo/efectos adversos , Vasculitis/inducido químicamente , Vasculitis/patología , Adolescente , Adulto , Niño , Femenino , Humanos , Enfermedades del Complejo Inmune/inmunología , Enfermedades del Complejo Inmune/patología , Inmunosupresores/uso terapéutico , Riñón/efectos de los fármacos , Riñón/inmunología , Riñón/patología , Enfermedades Renales/inmunología , Enfermedades Renales/patología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Vasculitis/inmunologíaRESUMEN
Safety concerns about di-(2-ethylhexyl)phthalate (DEHP), a plasticizer and a probable endocrine disruptor, have attracted considerable public attention, but there are few studies about long-term exposure to DEHP. DEHP toxicity is thought to involve peroxisome proliferator-activated receptor alpha (PPARalpha), but this contention remains controversial. For investigation of the long-term toxicity of DEHP and determination of whether PPARalpha mediates toxicity, wild-type and PPARalpha-null mice were fed a diet that contained 0.05 or 0.01% DEHP for 22 mo. PPARalpha-null mice that were exposed to DEHP exhibited prominent immune complex glomerulonephritis, most likely related to elevated glomerular oxidative stress. Elevated NADPH oxidase, low antioxidant enzymes, and absence of the PPARalpha-dependent anti-inflammatory effects that normally antagonize the NFkappaB signaling pathway accompanied the glomerulonephritis in PPARalpha-null mice. The results reported here indicate that PPARalpha protects against the nephrotoxic effects of long-term exposure to DEHP.
Asunto(s)
Dietilhexil Ftalato/toxicidad , Glomerulonefritis/inducido químicamente , Glomerulonefritis/prevención & control , PPAR alfa/metabolismo , Plastificantes/toxicidad , Animales , Secuencia de Bases , Dieta , Dietilhexil Ftalato/administración & dosificación , Dietilhexil Ftalato/análogos & derivados , Dietilhexil Ftalato/sangre , Glomerulonefritis/genética , Glomerulonefritis/metabolismo , Enfermedades del Complejo Inmune/inducido químicamente , Enfermedades del Complejo Inmune/genética , Enfermedades del Complejo Inmune/metabolismo , Enfermedades del Complejo Inmune/prevención & control , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Ratones , Ratones Noqueados , Estrés Oxidativo/efectos de los fármacos , PPAR alfa/deficiencia , PPAR alfa/genética , Plastificantes/administración & dosificación , ARN Mensajero/genética , ARN Mensajero/metabolismoRESUMEN
The purpose of this report was to present 2 cases of similar erythematous lesions in patients using Listerine Cool Mint PocketPaks Oral Care Strips. The first case, a 44-year-old female presented with an erythematous, well-defined, macular lesion centrally located on the midhard palatal gingiva. The second case involved a healthy 7-year-old Hispanic female who presented with a similar lesion and the same clinical presentation. Both presented as solitary lesions involving the height of the palate, with bilateral congruency to the mid-palatal suture line. The lesions were square in shape, with 3 sides being distinctly demarcated. The fourth side feathered anteriorly, gradually disappearing as it approached the anterior third of the palate. On verbal questioning in both cases, no discomfort or irritation was indicated in the medical history or by the patient. Both patients indicated regular use of Listerine Cool Mint PocketPaks Oral Care Strips. Treatment consisted of a: (1) recommendation that the strips be discontinued; and (2) re-evaluation of the lesions at the follow-up appointments to make assessments for any possible changes in lesion color, size, or shape. Following discontinuance of the Oral Care Strips, the lesions disappeared. Follow-up appointments suggest an allergic contact focal erythema caused by prolonged contact with the irritant, in this case due to use of Listerine Cool Mint PocketPaks Oral Care Strips.